Health Care Sector Update for 03/10/2015: ACRX, VRX, RDUS


Shutterstock photo

Top Health-care stocks:

JNJ: -0.9%

PFE: -0.7%

ABT: flat

MRK: -0.5%

AMGN: -0.4%

Health-care shares were generally lower in pre-market trade Tuesday.

In health-care stocks news, AcelRx Pharmaceuticals ( ACRX ), a development-stage pharmaceutical company, has been downgraded by analysts at Jefferies to a hold rating from a buy. The firm also slashed its price target on the stock in half to $6 from $12 a share.

Shares in the company were unchanged at $5.51 during pre-market trade. Over the past 52 weeks, the company has traded between $5.07 and $13.40.

Meanwhile, Valeant Pharmaceuticals ( VRX ) is selling $9.6 billion in senior notes in a private offering for use in funding the previously announced acquisition of bowel drug maker Salix Pharmaceuticals ( SLXP ), along with the associated costs.

Shares in the company were unchanged at $204.69 during pre-market trade. Over the past 52 weeks, the company has traded between $106 and $205.51.

And Radius Health ( RDUS ), which is focused on developing differentiated therapeutics for patients with osteoporosis, reported its Q4 net loss widened as expenses rose.

Shares in the company were flat at $47.79 during pre-market trade. Over the past 52 weeks, the company has traded between $7.46 and $51.22.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.



This article appears in: Investing , Commodities
Referenced Symbols: ACRX , VRX , SLXP , RDUS


More from MT Newswires

Subscribe






MT Newswires
Contributor:

MT Newswires

Market News, Commodities
Follow on:








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com